Format

Send to

Choose Destination
Anticancer Res. 2015 Jul;35(7):3979-85.

Patients with Non-small Cell Lung Cancer Analyzed for EGFR: Adherence to Guidelines, Prevalence and Outcome.

Author information

1
Department of Medical Sciences, Respiratory Medicine, Uppsala University, Uppsala, Sweden martin.sandelin@medsci.uu.se.
2
Regional Cancer Center Uppsala-Örebro, Uppsala, Sweden.
3
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden Unit of Molecular Pathology, Uppsala University Hospital, Uppsala, Sweden.
4
Section of Oncology, Department of Radiology, Oncology and Radiation Sciences, Uppsala University, Uppsala, Sweden.
5
Department of Oncology, Gävle Hospital, Gävle, Sweden.
6
Department of Respiratory Medicine, Gävle Hospital, Gävle, Sweden Centre for Research and Development Uppsala University/County Council of Gävleborg, Gävle, Sweden.
7
Department of Medical Sciences, Respiratory Medicine, Uppsala University, Uppsala, Sweden.

Abstract

BACKGROUND:

Epidermal growth factor receptor (EGFR) analysis is the first molecular test introduced in the routine care of patients with non-small cell lung cancer (NSCLC). In the present study, we describe the prevalence of EGFR mutations and the adherence to testing and treatment guidelines in a population-based Swedish NSCLC cohort.

MATERIALS AND METHODS:

Patients with NSCLC analyzed for EGFR mutations were identified and their characteristics and survival data were retrieved. We compared the study cohort to a matched lung cancer population.

RESULTS:

The EGFR mutation frequency was 10%. Mutations were enriched in women and in adenocarcinoma cases. Out of patients with advanced-stage NSCLC with non-squamous histology, only 49% were referred for EGFR analysis. Out of the patients with EGFR mutation and advanced disease, only 38% received EGFR-tyrosine kinase inhibitor (TKI) in first-line therapy.

CONCLUSION:

The EGFR-mutated NSCLC population studied is similar to other Western populations. Surprisingly, a large proportion of patients were not referred for EGFR analysis. Out of the patients with EGFR mutation, fewer than 40% received EGFR-TKI as first-line treatment. Our results highlight the need for follow-up of treatment and diagnostic algorithms in routine healthcare.

KEYWORDS:

EGFR; Non-small cell lung cancer; mutation; outcome; population; prevalence

PMID:
26124345
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center